ClinicaliQ Trial Snapshot
- Magseed Pro(R)/ Sentimag(R) Gen3 — Recruiting • Non-phase study • Oncology • NCT05142787.
- What is being tested: The Magseed Pro®/Sentimag® Gen3 system—a magnetic marker and detection device combination—is being evaluated for safely and effectively marking suspicious or biopsy-proven positive axillary lymph nodes and soft tissue lesions (including cancers and pre-cancerous changes) to guide surgical intervention.
- Patient eligibility overview: The trial includes patients with suspicious or confirmed malignant axillary lymph nodes and those with soft tissue lesions requiring biopsy or surgical management, though specific age, staging, and histology criteria should be verified in the full protocol.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast
Eligibility Snapshot
- : * Participant is willing and able to give informed consent for participation in the study * Participant is aged 18 years or older at the time of consent. * Patients requiring breast lesion/axillary node marking and excision
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.